Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus rhamnosus HN001 and Reduced Prevalence of Atopic Sensitization

Research synthesisModerate evidenceMixed effect size3 studies · 2 beneficial · 1 neutral · 0 harmful

Across 3 randomized controlled trials, 2 reported beneficial effects (one statistically significant, one trending) of Lactobacillus rhamnosus HN001 on reducing atopic sensitization, with effect sizes ranging from small to moderate. The most studied dose was 6×10^9 CFU/day, and the evidence primarily involves infants and their mothers, especially those at high risk for allergies. One neutral study used maternal-only supplementation, suggesting that direct infant administration may be necessary.

  • Effective dose range: 6×10^9 CFU/day
  • Studied populations: infants and their mothers, particularly those at high risk for allergic disease

Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Only 1 of 3 studies reached statistical significance, and the beneficial effect was not consistently observed when supplementation was given only to mothers during pregnancy and breastfeeding.

Generated May 12, 2026
Doses used in studies
  • CFU/day: 6 billion (median 6 billion, IQR 6 billion–6 billion) — 3 studies
Safety in these studies
3 of 3 papers
Back to top